July 12th 2024
This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
PER® Psychiatry Summit
November 7, 2024
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Real Psychiatry 2025
January 17 - 18, 2025
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Confounding Factors in TRD (Part 1): The Role of Subtyping and Bipolarity
July 19th 2012The current system of payment for mental health care in the US can lead, or even incentivize, clinicians to focus on and code for Axis I disorders and their more readily reimbursed psychopharmacological treatment approaches.
Read More
Study Reports TMS Therapy Helps Patients With MDD
May 16th 2012New data show that patients with unipolar, non-psychotic major depressive disorder (MDD) receiving transcranial magnetic stimulation (TMS) achieved significant improvements in both depression symptoms and in quality of life measurements.
Read More
Wonderful News: DSM-5 Finally Begins Its Belated And Necessary Retreat
May 5th 2012For the first time in its history, DSM-5 has shown some flexibility and capacity to correct itself. Hopefully, this is just the beginning of what will turn out to be a number of other necessary DSM-5 retreats.
Read More
The Loman Family’s Lessons for the Young Psychiatrist
April 19th 2012After seeing Death of a Salesman on Broadway, I knew I had seen something extraordinary-but it was only after a few days’ separation from the performance when my mind cleared and my emotions settled that I realized 2 of the reasons that made me very appreciative to see this play as a young psychiatrist.
Read More
Does Evidence-Based Medicine Discourage Richer Assessment of Psychopathology and Treatment?
April 5th 2012The paradigm for modern psychiatry is evidence-based medicine (EBM)-it represents proven treatments for defined diagnoses. But there are major problems with this position, starting with the fact that while they are superior to placebo, evidence-based treatments too often are ineffective.
Read More
Introduction: Strategies for Treatment
April 3rd 2012When thinking about recent advances in psychopharmacology, we often point to new molecules with similar mechanisms of action but with better safety and tolerability profiles, or to molecules with novel mechanisms that effect positive change greater than that with existing treatments.
Read More